Retrophin gets licensing rights to Ligand's DARA program

02/21/2012 | Genetic Engineering & Biotechnology News

Retrophin paid $1 million upfront to obtain licensing rights to Ligand Pharmaceuticals' clinical-stage dual acting receptor antagonist of angiotensin and endothelin receptors program. Retrophin plans to develop DARA as treatment for severe kidney disease and initially focal segmental glomerulosclerosis. Ligand could also receive more than $75 million in milestone fees plus 9% royalties.

View Full Article in:

Genetic Engineering & Biotechnology News

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Manager/Senior Manager, Health Services Analytics
Avalere Health
Washington, DC
Manager/Senior Manager, Health Economist
Avalere Health
Washington, DC
Director, Health Services Analytics
Avalere Health
Washington, DC
Director/Vice President. Health Actuary
Avalere Health
Washington, DC
Attorney
U.S. DEPARTMENT OF HEALTH & HUMAN SERVICES Food and Drug Administration Office of the Chief Counsel
Silver Spring, MD, MD